Travelers' Diarrhea, New Insights

Travelers' diarrhea is one of the most common health problems that afflict individuals from developing countries visiting less affluent regions of the world. Bacterial enteropathogens, particularly diarrheagenic Escherichia coli are the most common agents with a minority of cases due to the protozoan pathogens Cryptosporidium and Giardia or viruses such as norovirus. Although travelers' are aware of risk factors, they rarely exercise dietary precautions aimed at prevention. Fluoroquionoles, azithromycin, and rifaximin, a nonabsorbable antibiotic can decrease duration of illness. Antibiotic prophylaxis is effective and of use in selected circumstances.

[1]  H. Dupont,et al.  Association of Putative Enteroaggregative Escherichia coli Virulence Genes and Biofilm Production in Isolates from Travelers to Developing Countries , 2006, Journal of Clinical Microbiology.

[2]  K. Lacombe,et al.  Absence of efficacy of nonviable Lactobacillus acidophilus for the prevention of traveler's diarrhea: a randomized, double-blind, controlled study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  H. Dupont,et al.  A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. , 2006, The American journal of tropical medicine and hygiene.

[4]  H. Dupont,et al.  Fecal cytokines and markers of intestinal inflammation in international travelers with diarrhea due to Noroviruses , 2006, Journal of medical virology.

[5]  David N. Taylor,et al.  Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  H. Dupont,et al.  A Randomized, Double-Blind, Placebo-Controlled Trial of Rifaximin To Prevent Travelers' Diarrhea , 2005, Annals of Internal Medicine.

[7]  K. Schwab,et al.  Prevalence of Norovirus among Visitors from the United States to Mexico and Guatemala Who Experience Traveler's Diarrhea , 2005, Journal of Clinical Microbiology.

[8]  H. Dupont,et al.  United States male students who heavily consume alcohol in Mexico are at greater risk of travelers' diarrhea than their female counterparts. , 2006, Journal of travel medicine.

[9]  A. McNab,et al.  Interventions to prevent and control food-borne diseases associated with a reduction in traveler's diarrhea in tourists to Jamaica. , 2006, Journal of travel medicine.

[10]  H. Dupont,et al.  Epidemiology of travelers' diarrhea: details of a global survey. , 2006, Journal of travel medicine.

[11]  H. Dupont,et al.  Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  H. Dupont,et al.  Post-Diarrhea Chronic Intestinal Symptoms and Irritable Bowel Syndrome in North American Travelers to Mexico , 2004, The American Journal of Gastroenterology.

[13]  H. Dupont,et al.  The role of diet in the treatment of travelers' diarrhea: a pilot study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  R. Spiller.  Inflammation as a basis for functional GI disorders. , 2004, Best practice & research. Clinical gastroenterology.

[15]  R. Hegde,et al.  The P Domain of Norovirus Capsid Protein Forms Dimer and Binds to Histo-Blood Group Antigen Receptors , 2004, Journal of Virology.

[16]  D. Sack,et al.  Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  H. Dupont,et al.  Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  D. Milewicz,et al.  Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region. , 2003, The Journal of infectious diseases.

[19]  B. Lowe,et al.  Therapy of travelers’ diarrhea with rifaximin on various continents , 2003, American Journal of Gastroenterology.

[20]  P. Gounon,et al.  Identification of an Aggregative Adhesion Fimbria (AAF) Type III-Encoding Operon in Enteroaggregative Escherichia coli as a Sensitive Probe for Detecting the AAF-Encoding Operon Family , 2002, Infection and Immunity.

[21]  H. Dupont,et al.  Enteric Pathogens in Mexican Sauces of Popular Restaurants in Guadalajara, Mexico, and Houston, Texas , 2002, Annals of Internal Medicine.

[22]  Z. Jiang,et al.  Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  Z. Jiang,et al.  Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  H. Dupont,et al.  Rifaximin: A Nonabsorbed Antimicrobial in the Therapy of Travelers’ Diarrhea , 1998, Digestion.

[25]  C. Hoge,et al.  Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.